Navigation Links
Combo Therapy Helps Multiple Myeloma Patients
Date:12/12/2008

Three-quarters of those who had relapsed saw disease stabilize or improve, study shows

FRIDAY, Dec. 12 (HealthDay News) -- A new combination of medicines designed to boost immune function can help some multiple myeloma patients, according to interim results from an ongoing Mayo Clinic study.

The researchers found that combining a new immunomodulatory drug called pomalidomide with dexamethasone (pom/dex) improved or stabilized disease in 76 percent of multiple myeloma patients who'd relapsed after previous treatment.

Multiple myeloma, a cancer that begins in white blood cells called plasma cells, affects about three in 100,000 people per year. There is no cure, but the disease can be managed. Immunomodulatory drugs interfere with cancer cell growth and stimulate the immune system to attack cancer cells.

The Mayo study began in November 2007 and has enrolled 60 patients, who took 2 milligrams of pomalidomide orally a day for a 28-day cycle and 40 mg of dexamethasone orally on days 1, 8, 15 and 22. They also took 325 mg of aspirin daily to prevent blood clots, a potential problem for patients taking immunomodulatory drugs.

Of the 60 patients, 58 percent have responded to therapy with at least a 50 percent decrease in detectable tumor burden as measured by blood protein levels, a marker for myeloma. This includes one patient who achieved complete remission, 14 patients who achieved at least a 90 percent decrease in blood proteins and 11 patients who remained stable.

"These are high remission rates, and they happened quickly," lead researcher and hematologist Dr. Martha Lacy said in a Mayo news release.

Side effects included anemia and declines in blood counts. In most patients, these side effects were mild.

Pomalidomide, also called CC-4047, belongs to the same class of immunomodulatory drugs as thalidomide and lenalidomide, both of which have been approved by the U.S. Food and Drug Administration for use with dexamethasone for multiple myeloma patients who've had previous treatment.

The Mayo researchers found that pom/dex was helpful in 29 percent of patients who didn't respond to lenalidomide.

The interim results of the study, funded by Celgene, were presented at the annual meeting of the American Society of Hematology.

"We are excited about the potential of this drug combination to significantly help patients with myeloma. Based on these encouraging results, we are expanding the study to include other patient populations that may benefit from this therapy," Lacy said.

More information

The American Cancer Society has more about multiple myeloma.



-- Robert Preidt



Mayo Clinic, news release, Dec. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Blood Pressure Pill Combo More Effective Than Diuretics
2. U.S. Cancer Rate-Death Rate Combo Drops for 1st Time
3. Combo Treatment Best for Anxiety Disorder in Kids
4. Vaginal/Caesarean combo delivery of twins safe, UT Southwestern-led research finds
5. Drug/radiation combo may help shrink established tumors
6. Inverness Medical Innovations Announces 4th Generation Rapid HIV Test - Determine(TM) HIV-1/2 Ag/Ab Combo
7. Once-Daily Combo Works for New HIV Patients
8. Two-Drug Combo Reduces Diabetic Kidney Damage
9. 3-Drug Combo Improves Advanced Pancreatic Cancer Outcomes
10. Combo Therapy Knocks Out Melanoma Tumors
11. Combo Kidney-Pancreas Transplant Boosts Survival in Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combo Therapy Helps Multiple Myeloma Patients
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology: